Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Regulators say they’ll review Vertex’s new cystic fibrosis drug combo

By , Globe Staff

If approved, it would be the Boston biotech’s third treatment for the lung disease.

Bristol-Myers pays $300 million for Cambridge biotech

By , Globe Staff

Drug giant Bristol-Myers Squibb Co. has agreed to pay $300 million to buy a two-year-old Cambridge biotech developing treatments for cancers and other diseases.

Vertex reports strong findings from cystic fibrosis drug trials

By , Globe Staff

A combination treatment dramatically improved lung function, lifting hopes for a medicine that could treat 90 percent of CF patients.

With ads, rare for a medical device maker, Boston Scientific shifts gears

By , Globe Staff

The Marlborough medical device company is moving into the fast-growing cardiology markets.